33 results about "Fibrosarcoma" patented technology

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein.

The invention discloses a fully-humanized anti-human interleukin 17A single-chain antibody, relates to the technical field of genetically engineered antibodies and specifically relates to a fully-humanized antibody fragment which is genetically engineered, screened, expressed and provided with special affinity with interleukin 17A (IL-17A). The genetically engineered antibody fragment is connected with a heavy chain region and a light chain region end to end by virtue of a soft connecting fragment. By constructing a great-capacity natural phage antibody library, an antibody fragment with special adsorption capacity on IL-17A is obtained by biological elutriation. The antibody fragment is constructed into a full-length antibody, so that the reaction of IL-17A on interleukin 6(IL-6) released by a human fibrosarcoma cell HT1080 can be inhibited by virtue of eukaryotic secretory expression and affinity purification. The antibody fragment disclosed by the invention can be used for detecting and treating rheumatoid arthritis.

The invention discloses an amino acid positron emission tomography (PET) imaging agent, and a preparation method and application thereof. The imaging agent belongs to the field of N-substituted positron nuclide labeled glutamic acid compound and has a structure as shown in the specification; and the L*represents -11CH3, CH2CH218F, and -COCH (18F) CH3. The novel imaging agent N-(2-18F-fluoropropionyl)-glutamic acid shows good tumor PET imaging sensitivity and specificity, has high uptake on tumor (such as S180 fibrosarcoma), and no obvious uptake on other tissues and organs (except for bladder) in the body, and indicates high tumor to background ratio. In vitro-in vivo experiments show that N-(2 - 18F -fluoropropionyl)-glutamic acid is stable in vitro and in vivo and shows good pharmacokinetic properties.

Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.

The invention belongs to the technical field of medicines, in particular relates to a physalin A extracting process and medical application thereof, in particular relates to a novel application of physalin A in preparation of an anti-tumor dug and in particular relates to the use of physalin A in treatment of human fibrosarcoma and human malignant melanoma. After process optimization, the extracting rate of physalin A is 0.2133%. Physalin A can be used for inhibiting the growth of various tumor cells, particularly has obvious inhibiting action on the growth of the human fibrosarcoma and human malignant melanoma, but does not inhibit the activities of the human normal cells obviously. The mechanism is that the downstream caspase family-associated protein is activated by activating Fas death receptors, so that the tumor cells are induced to generate apoptosis. Meanwhile, the physalin A can be used for inducing the tumor cells to generate autophagy for achieving autophagy antagonism apoptosis in the HT1080 and the A375-S2 cells; and the p53 protein and the MAPK (Mitogen-Activated Protein Kinase)-familty p38 protein have a key regulation effect. The physalin A can be used for preparing a digestive tract dosage form or a non-digestive tract dosage form, which can be used for treating tumors including the human fibrosarcoma and human malignant melanoma.

The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and / or human breast cancer cell.

The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.

The invention provides paclitaxel derivatives with a general structural formula (I) as described in the invention. The invention further provides application of the paclitaxel derivatives in preparation of drugs used for preventing or treating fibrosarcoma, liver cancer, lung cancer, leukemia, epidermoid carcinoma, breast cancer, prostatic cancer, lymphoma, stomach cancer, myeloma and pancreatic cancer. The derivatives synthesized in the invention have better water-solubility compared with paclitaxel and are superior to paclitaxel in the aspect of a plurality of anticancer effects.

The invention relates to sym-triazine derivative compounds containing sym-tetrazine rings and a preparation method thereof and belongs to the technical field of pharmaceutical synthesis and medicines. The sym-triazine derivative compounds containing sym-tetrazine rings provided by the invention are new sym-triazine derivative compounds containing sym-tetrazine rings with higher biological activity and a certain inhibition effect on tumor cells, and are synthesized from cyanuric chloride, substituted sym-tetrazine hydrazine and di-substituted ammonia used as raw materials by the synthesis method. The synthesis method has the advantages of readily available raw materials, simple and convenience process, easiness for operation and lower synthesis cost, and is suitable for industrial production. Through in-vitro test of the inhibition effect on the tumor cells, the sym-triazine derivative compounds containing sym-tetrazine rings provided by the invention have stronger inhibition effect onthe tumor cells, such as human fibrosarcoma, human breast cancer, human lung cancer, human colon cancer and other tumor cells.

The present disclosure relates to bifunctional compounds, ULM- L-PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and / or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

The invention provides a gel for treating colpitis and a preparation method thereof. The method comprises the following steps: taking 20 parts of lysionotus paucifloru maxuim, 18 parts of polygonum viviparum, 15 parts of mosla dianthera, 28 parts of picris divaricata, 14 parts of white wax leaves, 20 parts of shiny-leaved yellowhorn, 1 part of carbomer, 20 parts of propylene glycol, 2 parts of ethyl alcohol, 2 parts of azone, 3 parts of triethanolamine and 250 parts of distilled water; adding water at the weight being 10 times of the weight of the medicinal materials; soaking for 0.5h and decocting for 1 hour; filtering residues; adding water at the weight being 8 times of the weight of the medicinal materials; decocting for 1 hour; filtering the liquor. The special concentrating and drying device is adopted. The gel for treating colpitis can be applied for preparing the drug for restraining human fibrosarcoma HT-1080 cell proliferation.

The establishing process of mesoblastic nephroma animal model includes the following steps: primary culture of embryo muscle cell of mammal; subculture after the cell grows to fuse; extracorporeal culture for 3-8 months to obtain cloning cell in the culture and eternal tumor cell line; passaging for several times after malignant cell transformation to obtain monoclinic cell strain via monoclonal culture; nude mouse hypodermic transplantation of the monoclinic cell strain; identifying the tumor cell strain by means of immunocytochemistry method or molecular biological method; transplanting the obtained fibrosarcoma cell strain to nude mouse renal diolame to obtain the mesoblastic nephroma animal model. The mesoblastic nephroma animal model provides the research of mesoblastic nephroma pathogenesis and treatment with technological platform.

The invention discloses an application of miltipolone or pharmaceutically acceptable salts thereof in the preparation of medicines for preventing or curing diseases related to Fe2+. A cancer cell inhibiting effect of the medicines prepared by the miltipolone or the pharmaceutically acceptable salts thereof realizes the purpose of anticancer through inhibiting cancer cell proliferation ; and particularly, the invention provides new choices of the medicines for curing or preventing human lung cancer, human liver cancer, human cervical carcinoma, human breast carcinoma, leukocythemia, fibrosarcoma, or gastric cancer.

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.

The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and / or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand whichbinds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disordersthat result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein.

The invention belongs to the field of biological medicine, and relates to basic fibroblast growth factor activated fibroblast as well as a preparation method and an application thereof. The invention aims at solving the technical problem for providing a new selection for tumour treatment. The invention provides a tumour universal type fibroblast vaccine, and a main active component of the vaccine is inactivated basic fibroblast growth factor activated fibroblast. The invention aims at providing the novel cell vaccine for researching and developing tumour fibroblast; and the vaccine can inhibit a plurality of tumours, and is used as a universal antineoplastic vaccine for control of colorectal carcinoma, lung cancer, fibrosarcoma and the like.

The invention relates to an mRNA vaccine and a kit and application thereof. The mRNA vaccine is prepared from an epitope antigen gene sequence of Kras, an epitope antigen gene sequence of Survivin andan epitope antigen sequence of CEA, wherein the Kras, the Survivin and the CEA are separated. The kit includes the mRNA vaccine and a PD-1 antibody. The antibody can be used for preparing medicine for treatment of diseases such as rectal cancer, liver cancer, pancreatic cancer, breast cancer, bladder cancer, fibrosarcoma, renal cancer, leukemia, lung cancer, white lymphoma, lymphoma, melanoma, myeloma, neuroblastoma, plasmacytoma and prostate cancer. The mRNA vaccine is prepared by combining epitope antigens of the three non-drugable targets including the KRas, the Survivin and the CEA for the first time, thereby achieving the purpose of inhibiting tumor growth.

The invention discloses a rabbit anti-human TRK protein monoclonal antibody, can specifically recognize the TRK and / or TRK fusion protein expressed by cells, has stable performance and high titer, hasno cross-reaction with other proteins in the cell, and has certain medical basic research value. The invention also relates to the use of the above monoclonal antibody for the preparation of immunohistochemical detection tools for detecting TRK and / or TRK fusion protein. The application adopts an immunohistochemical method to detect TRK and / or TRK protein of tumor cells including lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colorectal carcinoma, soft tissue sarcoma, salivary gland, infant fibrosarcoma, appendix cancer, breast cancer, cholangiocarcinoma, pancreatic cancer, and the like. The monoclonal antibody provides a powerful scientific reference for the treatment of TRK kinase inhibitors, effectively reduces the cost of treatment, and has important application value.

The present invention relates to peptides that inhibit the excessive production and / or accumulation of an extracellular matrix in an organ or tissue. The peptides of the invention have the general formula sequence Xa-Leu-Gln-Gly-Xb (SEQ ID NO: 1) wherein Xa is selected from the group consisting of Pro-Gly, Gly and Ac-Gly and Xb is selected from the group consisting of Glu and Glu-NH2, which peptides are capable of inhibiting excessive production and excessive accumulation of extracellular matrix in organs or tissues in the form of linear peptides and cyclic peptides. In particular, the peptides disclosed herein are useful for the treatment of fibrotic disorders characterized by excessive accumulation of extracellular matrix, such as liver fibrosis, cirrhosis, pulmonary fibrosis, chronic respiratory failure, cardiac fibrosis, ischemic heart disease, heart failure, diabetic nephropathy, glomerulonephritis, myelofibrosis, and various types of cancers, such as liver fibrosis, liver cirrhosis, pulmonary fibrosis, chronic respiratory failure, cardiac fibrosis, ischemic heart disease, heart failure, diabetic nephropathy, glomerulonephritis, myelofibrosis, and the like. Such as breast cancer, uterine cancer, prostate cancer, pancreatic cancer, colon cancer, skin cancer, blood cell cancer, central nervous system cancer, fibromyoma, fibroma, fibroadenoma and fibrosarcoma.

The invention provides an extracting method of a plant composite containing mycelia of cultured cordyceps sinensis. The plant composite is prepared from the raw material herbs of 100 g of mycelia of cultured cordyceps sinensis, 60 g of gentiana apiata, 80 g of salvia chinensis and 160 g of Chinese pennisetum. The plant composite is prepared by the adoption of the microwave extracting method, in this way, the content is greatly increased, and the usage amount is reduced. The invention further provides an application of the plant composite containing the mycelia of cultured cordyceps sinensis in preparation of medicine for restraining C57BL / 6 mice fibrosarcoma S180 cell proliferation.

The invention reveals that the V-Maf bird myofascia fibrosarcoma cancer gene homolog G (MAFG) is a regulation target of cholesterol homeostasis, and the MAFG and a regulator thereof can be used as a new way for developing drugs for high cholesterol related diseases (such as hypercholesterolemia and atherosclerosis) or low cholesterol related diseases.

The invention discloses an application of miltipolone or pharmaceutically acceptable salts thereof in the preparation of medicines for preventing or curing diseases related to Fe2+. A cancer cell inhibiting effect of the medicines prepared by the miltipolone or the pharmaceutically acceptable salts thereof realizes the purpose of anticancer through inhibiting cancer cell proliferation ; and particularly, the invention provides new choices of the medicines for curing or preventing human lung cancer, human liver cancer, human cervical carcinoma, human breast carcinoma, leukocythemia, fibrosarcoma, or gastric cancer.

The invention provides new application of valeriana jatamansi jones total flavonoids, in particular application in preparing a medicament for treating liver cancer or fibrosarcoma. The invention also provides a medicinal composition for treating liver cancer or fibrosarcoma. The valeriana jatamansi jones total flavonoids have remarkable inhibiting effect on the growth of tumors in mice inoculatedwith liver cancer H22 and fibrosarcoma S180 so as to show that the valeriana jatamansi jones total flavonoids have obvious effect of resisting the liver cancer and the fibrosarcoma and provide a new medicament selection for clinic.

The present invention relates to a hydroxyapatite and / or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and / or a radiotherapeutic agent.

Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16 / p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.

The invention provides an extracting method of a plant composite containing pleurotus nebrodensis. The plant composite is prepared from the raw material herbs of 100 g of pleurotus nebrodensis, 40 g of syzygium buxifolium, 80 g of sensitive joint vetch leaves and 160 g of clerodendrum fortunatum. The plant composite is prepared by the adoption of the microwave extracting method, in this way, the content is greatly increased, and the usage amount is reduced. The invention further provides an application of the plant composite containing the pleurotus nebrodensis in preparation of medicine for restraining human fibrosarcoma HT-1080 cell proliferation.

A method for treating a cancer by administering a therapeutically active composition for the treatment in a patient or human thereof, is disclosed. The method according to the present invention, comprises a step of administering to the human a pharmaceutical composition comprising a therapeutic amount of sodium thiosulfate (Na2S2O3) along with at least one of a pharmaceutical carrier and a pharmaceutical excipient. The carriers, or excipients are selected corresponding to the mode of administration to the patient with cancer includes gastric cancer, fibrosarcoma, pancreatic cancer, and head and neck carcinomas. The method further comprises a step of administering the said composition is any one of oral route, intravenous route, inhalation route, intra-vesical route, vaginal route, rectal route, sublingual route, ophthalmic route and topical route.